NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Bonvalot, Sylvie, PhD ; Rutkowski, Piotr L, Prof ; Thariat, Juliette, Prof ; Carrère, Sébastien, MD ; Ducassou, Anne, MD ; Sunyach, Marie-Pierre, MD ; Agoston, Peter, MD ; Hong, Angela, MBBS ; Mervoyer, Augustin, MD ; Rastrelli, Marco, MD ; Moreno, Victor, MD ; Li, Rubi K, MD ; Tiangco, Béatrice, MD ; Herraez, Antonio Casado, MD ; Gronchi, Alessandro, MD ; Mangel, László, MD ; Sy-Ortin, Teresa, MD ; Hohenberger, Peter, Prof ; de Baère, Thierry, Prof ; Le Cesne, Axel, MD ; Helfre, Sylvie, MD ; Saada-Bouzid, Esma, MD ; Borkowska, Aneta, MD ; Anghel, Rodica, MD ; Co, Ann, MD ; Gebhart, Michael, Prof ; Kantor, Guy, Prof ; Montero, Angel, MD ; Loong, Herbert H, MD ; Vergés, Ramona, MD ; Lapeire, Lore, MD ; Dema, Sorin, MD ; Kacso, Gabriel, MD ; Austen, Lyn, MD ; Moureau-Zabotto, Laurence, MD ; Servois, Vincent, MD ; Wardelmann, Eva, Prof ; Terrier, Philippe, MD ; Lazar, Alexander J, MD ; Bovée, Judith V M G, Prof ; Le Péchoux, Cécile, MD ; Papai, Zsusanna, Prof

The lancet oncology, 2019-08, Vol.20 (8), p.1148-1159 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível